149 COMMONWEALTH DRIVE, MENLO PARK, CA
Market cap: $4.3B (2/09/2026)
Price: $40.97
Overall Survival Primary Endpoint Met in Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
Termination of Distribution Services Agreement with Optime Care, Inc.
News
FDA Files New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Announces Second Quarter Financial Results and Provides Corporate Update
Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-8 POS